KR20140106814A - Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method - Google Patents
Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method Download PDFInfo
- Publication number
- KR20140106814A KR20140106814A KR1020130020892A KR20130020892A KR20140106814A KR 20140106814 A KR20140106814 A KR 20140106814A KR 1020130020892 A KR1020130020892 A KR 1020130020892A KR 20130020892 A KR20130020892 A KR 20130020892A KR 20140106814 A KR20140106814 A KR 20140106814A
- Authority
- KR
- South Korea
- Prior art keywords
- photosensitizer
- pheophorbide
- photodynamic
- dendron
- solvent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
본 발명은 광역학 진단 또는 치료용 광감작제 및 그 제조방법에 관한 것으로서, 더욱 상세하게는 pheophorbide a와 TEG 덴드론(triethylene glycol dendron)을 이용한 광역학 진단 또는 치료용 광감작제 및 그 제조방법에 관한 것이다.More particularly, the present invention relates to a photosensitizer for photodynamic diagnosis or treatment using pheophorbide a and a triethylene glycol dendron, and a method for producing the same. BACKGROUND OF THE
광역학 치료법(photodynamic therapy; PDT)은 빛, 광감작제, 체내 활성산소를 이용한 요법으로, 광감작제를 체내에 주사하고 특별한 파장을 갖는 레이저 빛을 질병부위에 조사하여 질병을 치료하는 방법이다. 암의 진단과 치료, 자가골수이식, 항생제, AIDS 치료, 피부이식 수술이나 관절염 등의 치료에 사용되고 있고, 그 응용 범위는 점차 확대되고 있는 추세이다.Photodynamic therapy (PDT) is a therapy using light, photosensitizer, active oxygen in the body, a method of injecting a photosensitizer into the body and irradiating a laser light having a specific wavelength to a disease site to treat the disease . Diagnosis and treatment of cancer, autologous bone marrow transplantation, antibiotics, AIDS treatment, skin transplantation surgery and arthritis, and the application range thereof is gradually increasing.
더욱 구체적으로, 암 치료에 사용되는 광역학 치료법은 광감작제 물질에 빛을 조사함으로써 체내 풍부한 산소와 외부 빛에 의한 화학반응으로 단일항 산소(singlet oxygen) 또는 자유 라디칼(free radical)이 생성되고 이러한 단일항 산소 또는 자유 라디칼이 정상세포는 그대로 보존시키면서 각종 병변부위나 암세포의 세포사멸을 유도하여 파괴함으로써 이루어진다.More specifically, the photodynamic therapy used in cancer treatment produces a singlet oxygen or free radical by chemical reaction of oxygen and external light in the body by irradiating light to the photosensitizer substance This is accomplished by inducing apoptosis and destroying various lesion sites or cancer cells while preserving normal cells as they are.
광역학 치료법은 암세포에만 선별적으로 축적되어 기존의 암치료법인 외과적 수술이나 방사선 요법, 약물 요법의 부작용 및 암치료 이후의 후유증 문제점을 보완해 주고, 국소 마취만으로도 시술이 가능하며, 암이 발병한 기관이라 하더라도 그 기능과 형태를 보존할 수 있을 뿐만 아니라 조직 손상이나 흉터 등도 남기지 않는 장점이 있다.Photodynamic therapy is selectively accumulated in cancer cells, and it can complement the existing cancer treatment methods such as surgical operation, radiation therapy, side effects of drug therapy, and aftereffects after cancer treatment, and can be performed by local anesthesia alone. Even an institution can preserve its function and form, and it does not leave tissue damage or scarring.
광감작제 물질로 포르피린류(porphyrins), 클로린류(chlorins), 박테리오클로린류(bacteriochlorins), 프탈로시아닌류(phthalocyanine), 5-아미노레불린 산류(5-aminolevulinic acid), 포르피센류(porphycenes) 등이 있고, 특허문헌으로는 대한민국 공개특허 10-2011-0035725(광역동 치료법에 이용되는 광감작제로서의 신규한 화합물), 대한민국 공개특허 10-2002-0038995(새로운 광역학 치료용 광감작제인 9-하이드록시피오포바이드 에이 유도체) 등이 있다.Examples of the photosensitizer include porphyrins, chlorins, bacteriochlorins, phthalocyanine, 5-aminolevulinic acid, porphycenes, etc. And Korean Patent Laid-Open No. 10-2011-0035725 (a novel compound as a photosensitizer used in the broad-band dynamic therapeutic method), Korean Patent Laid-Open No. 10-2002-0038995 (a new photo- Hydroxypivalobide derivatives) and the like.
그러나, 광역학 치료법을 임상에 적용하는데 있어 소수성 광감작제로 인해 비경구투여가 가능한 제형으로 만들기 어려운 문제점이 있다. 현재 광역학 암치료에 사용되고 있는 대부분의 광감작제들은 생체내 투여되었을 때 낮은 용해도, 생체분자들과의 부적절한 상호작용 및 광감작제들 간의 상호엉김 현상으로 암조직으로의 선택적 전달에 한계가 있고 낮은 광반응성을 보여 치료의 효과가 낮은 문제점이 있다.However, there is a problem that it is difficult to make a formulation capable of parenteral administration due to a hydrophobic photosensitizer in the application of photodynamic therapy to clinical use. Currently, most of the photosensitizers used in photodynamic cancer treatments have a low solubility when administered in vivo, inadequate interaction with biomolecules, and mutual entanglement between photosensitizers, which limits the selective delivery to cancer tissues Low photoreactivity and low therapeutic effect.
본 발명의 목적은 종래 난용성 광감작제보다 물에 대한 분산도가 향상되고 종래 광감작제보다 긴 장파장에서도 암세포에만 선별적으로 축적되어 우수한 세포 독성 효과를 지닌 고효율 광역학 진단 또는 치료용 광감작제를 제공함에 있다.It is an object of the present invention to provide a high-efficiency photodynamic diagnostic or therapeutic optical sensitization having excellent cytotoxic effect by accumulating only in cancer cells even at long wavelengths longer than the conventional photosensitizer, And the like.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 광역학 진단 또는 치료용 광감작제를 제공한다.In order to achieve the above object, the present invention provides a photodynamic agent for photodynamic diagnosis or treatment represented by the following general formula (1).
[화학식 1][Chemical Formula 1]
상기 광감작제는 650 내지 700 nm의 광선에 대하여 광감작 활성을 나타내는 것을 특징으로 한다.The photosensitizer is characterized by exhibiting photosensitizing activity against light rays of 650 to 700 nm.
상기 광감작제는 고형암을 광역학적으로 진단 또는 치료하는 것을 특징으로 한다.The photosensitizer is characterized by photodynamic diagnosis or treatment of solid tumors.
또한, 본 발명은 (1) pheophorbide a와 TEG 덴드론(triethylene glycol dendron)을 각각 용매에 녹인 후 혼합하여 교반하는 단계; (2) 감압 여과하는 단계; (3) 용매를 이용하여 추출하고 용매를 제거하는 단계; 및 (4) 칼럼 크로마토그래피로 분리하는 단계;를 포함하는 하기 화학식 1로 표시되는 광역학 진단 또는 치료용 광감작제의 제조방법을 제공한다.(1) dissolving pheophorbide a and a triethylene glycol dendron in a solvent, mixing and stirring the mixture; (2) vacuum filtration; (3) extracting with a solvent and removing the solvent; And (4) separation by column chromatography. The photodynamic agent for photodynamic diagnosis or treatment of the present invention is represented by the following general formula (1).
[화학식 1][Chemical Formula 1]
상기 (1)단계에서 TEG 덴드론(triethylene glycol dendron)은 1,3-DCC(1,3-dicyclohexyl carbodiimide) 및 4-DMAP(4-dimethyaminopyridine)와 함께 용매에 녹여 pheophorbide a와 혼합하는 것을 특징으로 한다.In step (1), the TEG dendron is dissolved in a solvent together with 1,3-DCC (1,3-dicyclohexyl carbodiimide) and 4-DMAP (4-dimethylaminopyridine) and mixed with pheophorbide a do.
상기 (1)단계에서 교반하는 시간은 40 내지 50 시간인 것을 특징으로 한다.The stirring time in the step (1) is 40 to 50 hours.
상기와 같은 본 발명에 따르면, pheophorbide a에 TEG 덴드론(triethylene glycol dendron)을 도입함으로써, 기존 pheophorbide a보다 물에 대한 분산도가 향상되고, 암세포 또는 암조직에 축적되어 근적외선 파장의 빛을 조사하면 단일항 산소 또는 자유 라디칼을 생성하여 세포독성을 나타내는 광역학 치료용 광감작제를 제공하는 효과가 있다.According to the present invention, by introducing a triethylene glycol dendron into pheophorbide a, the degree of dispersion of the pheophorbide a in water is improved compared with that of the existing pheophorbide a, and the light of near infrared wavelength is irradiated upon accumulation in cancer cells or cancer tissues There is an effect of providing a photosensitizer for photodynamic therapy which shows cytotoxicity by generating a single oxygen or free radical.
또한, 암세포 또는 암조직에 축적되어 형광이나 인광을 나타냄으로써 종양의 조기진단용으로 이용할 수 있는 광역학 진단용 광감작제를 제공하는 효과가 있다.The present invention also provides an optical sensitizer for photodynamic diagnosis which can be used for early diagnosis of tumors by showing fluorescence or phosphorescence accumulated in cancer cells or cancer tissues.
도 1은 pheophorbide a-TEG 덴드론 컨쥬게이트 유도체의 합성을 나타낸 도식.
도 2는 pheophorbide a-TEG 덴드론 컨쥬게이트의 MALDI-TOF에 의한 질량분석스펙트럼.
도 3은 pheophorbide a-TEG 덴드론 컨쥬게이트의 1H NMR(CDCl3) 스펙트럼.
도 4는 pheophorbide a-TEG 덴드론 컨쥬게이트의 UV-Vis 흡수스펙트럼.
도 5는 pheophorbide a-TEG 덴드론 컨쥬게이트의 형광스펙트럼.
도 6은 pheophorbide a-TEG 덴드론 컨쥬게이트의 MTT 분석 결과.
도 7은 pheophorbide a-TEG 덴드론 컨쥬게이트의 ANNEXIN Ⅴ-FITC 염색 결과.
도 8은 TEG 덴드론의 합성을 나타낸 도식.Figure 1 is a schematic representation of the synthesis of a pheophorbide a-TEG dendron conjugate derivative.
2 is a mass spectrometry spectrum of a pheophorbide a-TEG dendron conjugate by MALDI-TOF.
Figure 3 shows the 1 H NMR (CDCl 3 ) spectrum of the pheophorbide a-TEG dendron conjugate.
Figure 4 shows the UV-Vis absorption spectrum of the pheophorbide a-TEG dendron conjugate.
Figure 5 shows the fluorescence spectrum of a pheophorbide a-TEG dendron conjugate.
Figure 6 shows the results of MTT analysis of the pheophorbide a-TEG dendron conjugate.
Figure 7 shows the results of ANNEXIN V-FITC staining of the pheophorbide a-TEG dendron conjugate.
Figure 8 is a schematic representation of the synthesis of TEG dendron.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 하기 화학식 1로 표시되는 광역학 진단 또는 치료용 광감작제를 제공한다.The present invention provides a photodynamic agent for photodynamic diagnosis or treatment represented by the following general formula (1).
[화학식 1][Chemical Formula 1]
상기 광감작제는 650 내지 700 nm의 광선에 대하여 광감작 활성을 나타낸다.The photosensitizer exhibits photosensitizing activity against light rays of 650 to 700 nm.
상기 광감작제는 고형암을 광역학적으로 진단 또는 치료할 수 있다.The photosensitizer can diagnose or treat solid tumors photodynamically.
또한, 본 발명은 (1) pheophorbide a와 TEG 덴드론(triethylene glycol dendron)을 각각 용매에 녹인 후 혼합하여 교반하는 단계; (2) 감압 여과하는 단계; (3) 용매를 이용하여 추출하고 용매를 제거하는 단계; 및 (4) 칼럼 크로마토그래피로 분리하는 단계;를 포함하는 하기 화학식 1로 표시되는 광역학 진단 또는 치료용 광감작제의 제조방법을 제공한다.(1) dissolving pheophorbide a and a triethylene glycol dendron in a solvent, mixing and stirring the mixture; (2) vacuum filtration; (3) extracting with a solvent and removing the solvent; And (4) separation by column chromatography. The photodynamic agent for photodynamic diagnosis or treatment of the present invention is represented by the following general formula (1).
[화학식 1][Chemical Formula 1]
상기 (1)단계에서 TEG 덴드론(triethylene glycol dendron)은 1,3-DCC(1,3-dicyclohexyl carbodiimide) 및 4-DMAP(4-dimethyaminopyridine)와 함께 용매에 녹여 pheophorbide a와 혼합하는 것이 바람직하다.In step (1), the TEG dendron is preferably dissolved in a solvent together with 1,3-DCC (1,3-dicyclohexyl carbodiimide) and 4-DMAP (4-dimethylaminopyridine) and mixed with pheophorbide a .
상기 (1)단계에서 교반하는 시간은 40 내지 50 시간인 것이 바람직하다. 교반하는 시간이 상기 범위를 벗어날 경우 교반이 제대로 이루어지지 않아 수율이 떨어지며 본 발명에 따른 광감작제의 합성이 어렵다.The stirring time in the step (1) is preferably 40 to 50 hours. If the agitation time is out of the above range, stirring is not performed properly and the yield is low, and it is difficult to synthesize the photosensitizer according to the present invention.
상기 (3)단계에서 용매를 이용하여 추출하되, 3 내지 5회 반복적으로 추출하는 것이 바람직하다.In the step (3), it is preferable to extract by using a solvent, and repeatedly extract 3 to 5 times.
본 발명에 따른 광역학 진단 또는 치료용 광감작제는 종래 photofrin 또는 benzoporphyrin 등과 같이 630 nm의 흡수 파장대를 크게 벗어나지 못해 종양 크기에 따라 사용이 제한되는 단점을 보완하고, 세포 내에 존재하는 산소분자의 활성화에만 의존하여 세포 내의 산소분자가 부족한 말기암 환자의 종양을 치료하지 못했던 단점을 보완함으로써, 종래 광감작제보다 긴 장파장에서 효과적으로 산소분자를 활성화시키거나 산소분자가 없는 곳에서는 산소 라디칼을 활용해 종양 세포를 괴사시키는 수용성 덴드론이 도입된 고수용성 광감작제를 제공하고 있다.The photosensitizer for photodynamic diagnosis or treatment according to the present invention can not largely deviate from the absorption wavelength band of 630 nm, such as photofrin or benzoporphyrin, so that the use of the photosensitizer is limited depending on tumor size, , It is possible to effectively activate oxygen molecules at long wavelengths longer than conventional photosensitizers or to utilize oxygen radicals in the absence of oxygen molecules to compensate for the disadvantages of tumor And a water-soluble dendron which necroses the cells is introduced.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
실시예 1.Example 1.
TEG 덴드론(triethylene glycol dendron)은 도 8에서 보는 바와 같이 기 공지된 방법을 이용하여 합성하였다. 먼저, Triethylene glycol monomethyl ether에 Tosyl chloride를 이용해 Tosylation을 한 다음, Williamson ester 합성을 시행하였다. 세대수를 늘리기 위해 DEAD(Diethyl azodicarboxylate)와 pph3(Triphenylphosphine), 3,5-dihydroxybenzoate를 사용한 Mitsunobu방법과 LiAlH4를 이용한 환원반응으로 TEG 덴드론을 합성하여 pheophorbide a-TEG 덴드론 컨쥬게이트의 합성과정에 이용하였다.The triethylene glycol dendron was synthesized using a known method as shown in FIG. First, Tosylation was performed using Tosyl chloride in triethylene glycol monomethyl ether, followed by Williamson ester synthesis. To increase the number of generations, TEG dendron was synthesized by Mitsunobu method using DEAD (diethyl azodicarboxylate), pph 3 (Triphenylphosphine), 3,5-dihydroxybenzoate, and LiAlH 4 to synthesize pheophorbide a-TEG dendron conjugate Lt; / RTI >
250mL 2-neck 플라스크에 pheophorbide a(200mg, 0.34mmol)를 넣고 진공을 잡고 질소치환을 세번 반복하여 건조하였다.Pheophorbide a (200 mg, 0.34 mmol) was added to a 250 mL 2-neck flask, vacuum was applied, and nitrogen substitution was repeated three times.
상기 플라스크에 용매 THF(tetrahydrofuran) 100mL를 넣고, 여기에 TEG 덴드론(triethylene glycol dendron, 392.4mg, 0.405mmol), 1,3-DCC(1,3-dicyclohexyl carbodiimide 105mg, 0.51mmol) 및 4-DMAP(4-dimethyaminopyridine, 62.3mg, 0.51mmol)를 녹인 THF 50mL를 질소치환 하에 첨가하여 혼합하였다.To the flask was added 100 mL of a solvent THF (tetrahydrofuran), followed by addition of TEG dendron (392.4 mg, 0.405 mmol), 1,3-DCC (1,3-dicyclohexyl carbodiimide 105 mg, 0.51 mmol) (4-dimethyaminopyridine, 62.3 mg, 0.51 mmol) were dissolved in 50 mL of THF under nitrogen substitution.
이후, 40시간 동안 교반하고 반응이 종결된 용액을 감압여과하고, 생성물을 더 추출하기 위하여 감압여과 후 남아있는 여과물을 THF로 3회 추출한 다음 용매를 제거하였다. After stirring for 40 hours, the reaction solution was filtered under reduced pressure. To further extract the product, the filtrate was filtered under reduced pressure, extracted with THF three times, and then the solvent was removed.
미량으로 남아있는 수분을 제거하기 위해 무수 황산 나트륨(Na2SO4)으로 건조한 다음, 칼럼 크로마토그래피(silica, Ethyl acetate/Methanol=10:1)로부터 pheophorbide a-TEG 덴드론 컨쥬게이트를 얻었다.The residue was dried over anhydrous sodium sulfate (Na 2 SO 4 ) to remove the remaining water and then pheophorbide a-TEG dendron conjugate was obtained from column chromatography (silica, Ethyl acetate / Methanol = 10: 1).
실험예 1.Experimental Example 1
상기 실시예 1의 칼럼 크로마토그래피로부터 second fraction을 분리하여 MALDI-TOF에 의한 분자량 측정 및 1H NMR에 의한 분자구조 분석을 실시하였다(도 2 및 3 참조).The second fraction was separated from the column chromatography in Example 1, and the molecular weight was measured by MALDI-TOF and the molecular structure was analyzed by 1 H NMR (see FIGS. 2 and 3).
1H NMR(300 MHz; TMS) 측정은 용매 CDCl3를 사용하였다. 1 H NMR (300 MHz; TMS) measurement was performed using solvent CDCl 3 .
Pheophorbide a의 특성 피크는 1.24-2.19ppm에서 관측되었고, TEG 덴드론은 3.38ppm에서 O-CH3 말단부분의 12개의 H, 3.54-4.14ppm에서 C2H4O 메톡시부분의 48개의 H, 4.95ppm에서 G(0) 벤젠고리에 붙은 CH2에서 4개의 H, 6.46ppm에서 G(1) 벤젠고리에 존재하는 C-H에서 2개의 H 및 4.58ppm에서 G(1) 벤젠고리에 붙은 CH2에서 2개의 H를 측정하였다.The characteristic peaks of Pheophorbide a were observed at 1.24-2.19 ppm and the TEG dendron had 12 H of the O-CH 3 terminal portion at 3.38 ppm, 48 H of the C 2 H 4 O methoxy portion at 3.54-4.14 ppm, 4 H in CH 2 attached to the G (0) benzene ring at 4.95 ppm, 2 H in CH present in the G (1) benzene ring at 6.46 ppm and CH 2 attached to the G (1) benzene ring at 4.58 ppm Two Hs were measured.
상기 G는 generation의 약자로 TEG 덴드론의 세대수를 의미하며 G(0), G(1)은 하기 표 1에서 보는 바와 같다.G is an abbreviation of generation and means the number of generations of TEG dendron, and G (0) and G (1) are as shown in Table 1 below.
실험예 2.Experimental Example 2
THF(Tetrahydrofuran)와 Water 두 용매에 상기 실시예 1에서 얻은 Pheophorbide a-TEG 덴드론 컨쥬게이트를 각각 같은 농도로 녹여 UV-Vis 흡수스펙트럼을 측정하였다(도 4 참조). The UV-Vis absorption spectrum was measured by dissolving the Pheophorbide a-TEG dendron conjugate obtained in Example 1 at the same concentration in both THF (Tetrahydrofuran) and Water (FIG. 4).
용매 THF의 경우 411nm, 668nm에서, 용매 Water의 경우 400nm, 670nm에서 최대 흡수 피크를 나타내었다. The maximum absorption peaks at 411 nm and 668 nm for solvent THF and 400 nm and 670 nm for solvent water, respectively.
용매 THF의 경우 급격한 변화 형태를 띤 sharp한 피크들이 관찰되었고, 용매 Water의 경우 비교적 완만한 형태의 피크들이 관찰되었다. 이것은 물속에서 소수성인 pheophorbide a간의 응집에 의한 소광(quenching) 현상에서 비롯되었다고 할 수 있다. 하지만, 670nm 부근에서는 어느 정도 sharp한 피크도 관측할 수 있었고, 이것은 합성된 Pheophorbide a-TEG 덴드론 컨쥬게이트가 비교적 물과의 친화력이 있음을 나타낸다.In the case of solvent THF, sharp peaks with abrupt changes were observed, and in the case of solvent water, relatively gentle peaks were observed. This can be attributed to the quenching phenomenon caused by the aggregation of hydrophobic pheophorbide a in water. However, a somewhat sharp peak could be observed at around 670 nm, indicating that the synthesized Pheophorbide a-TEG dendron conjugate is relatively water affinity.
실험예 3.Experimental Example 3.
UV-vis 흡수스펙트럼과 마찬가지로 상기 실시예 1에서 얻은 pheophorbide a-TEG 덴드론 컨쥬게이트를 THF와 Water 용매에 각각 같은 농도로 녹인 다음, 같은 파장 659nm에서 여기시켜 형광스펙트럼을 측정하였다(도 5 참조).Similarly to the UV-vis absorption spectrum, the pheophorbide a-TEG dendron conjugate obtained in Example 1 was dissolved in the THF and water solvents at the same concentration, respectively, and excited at the same wavelength of 659 nm to measure the fluorescence spectrum (see FIG. 5) .
그 결과, THF와 Water 용매 각각 최대 670nm, 681nm에서 형광이 관측되었다. 용매가 Water일 경우 THF에 비해 형광의 크기는 작지만, 형광이 나타나는 것으로 보아 UV-vis 흡수스펙트럼과 마찬가지로 합성된 Pheophorbide a-TEG 덴드론 컨쥬게이트는 물과의 친화력이 있음을 알 수 있다.As a result, fluorescence was observed at a maximum of 670 nm and 681 nm in THF and water solvents, respectively. When the solvent is Water, the fluorescence intensity is smaller than that of THF. However, fluorescence appears, indicating that the synthesized Pheophorbide a-TEG dendron conjugate has affinity with water as in the UV-vis absorption spectrum.
이로써 pheophorbide a-TEG 덴드론 컨쥬게이트는 생체 적합한 광역학 진단 및 치료용 광감작제로서 활용이 가능할 것으로 판단된다.This suggests that the pheophorbide a-TEG dendron conjugate can be used as a photosensitizer for biocompatible photodynamic diagnosis and treatment.
실험예 4.Experimental Example 4.
상기 실시예 1에서 얻은 pheophorbide a-TEG 덴드론 컨쥬게이트의 세포 독성을 실험하기 위해 MTT 분석을 이용하여 세포사멸율을 측정하였다(도 6 참조).To determine the cytotoxicity of the pheophorbide a-TEG dendron conjugate obtained in Example 1, the cell death rate was measured using MTT assay (see FIG. 6).
ce6(Chlorin e6)은 pheophorbide a와 거의 동일한 구조와 물성을 가지는 클로린 유도체로서, TEG 덴드론이 붙은 pheophorbide a의 비교물질로 사용되었다.ce6 (Chlorin e6) is a chlorin derivative having almost the same structure and physical properties as pheophorbide a, and was used as a comparative substance of pheophorbide a with TEG dendron.
유방암 세포 MCF-7을 1×104cells/well로 96well plate에 분주하고 24시간 동안 배양하여 세포를 안정화하였다. 이후, 농도(0.3, 0.5, 1, 3, 5ug/ml)에 따라 약물을 투여하고 2시간 후 DPBS로 2번 세척한 다음 레이저(670nm, 50mW/cm2, 3분)를 조사하고 24시간 후 MTT 분석을 하였다. The cells were stabilized by culturing the breast cancer cells MCF-7 at a density of 1 × 10 4 cells / well on a 96-well plate for 24 hours. Subsequently, the drug was administered according to the concentration (0.3, 0.5, 1, 3, 5 ug / ml), followed by washing 2 times with DPBS for 2 hours and then 24 hours after irradiation with laser (670 nm, 50 mW / cm 2 , MTT analysis was performed.
그 결과, pheophorbide a-TEG 덴드론 컨쥬게이트의 경우 ce6와 비교해서 약 80%이상 유방암 세포가 사멸한 것으로 나타났다.As a result, about 80% or more of the pheophorbide a-TEG dendron conjugate was found to be killed in comparison with ce6.
또한, 광독성 실험을 위해 ANNEXIN V-FITC 염색을 하였다(도 7 참조). In addition, ANNEXIN V-FITC staining was performed for phototoxicity experiments (see FIG. 7).
유방암 세포 MCF-7을 1×104cells/well로 8well chamber slide에 분주하고 24시간 동안 배양하여 세포를 안정화하였다. 이후, 농도 1ug/ml의 약물을 투여하고 2시간 후 DPBS로 2번 세척한 다음 레이저(670nm, 50mW/cm2, 3분)를 조사하고 ANNEXIN V-FITC 염색을 통해 형광현미경(Fluorescence Microscopy)으로 분석하였다(BD Pharmingen).The cells were stabilized by culturing the breast cancer cells MCF-7 at a density of 1 × 10 4 cells / well in an 8-well chamber slide for 24 hours. After 2 hours, the cells were washed twice with DPBS, irradiated with laser (670 nm, 50 mW / cm 2 , 3 minutes), and analyzed by fluorescence microscopy through ANNEXIN V-FITC staining (BD Pharmingen).
암세포의 자가사멸(apoptosis)이 발생하면 인지질의 비대칭성이 손실되어 phosphatidylserine(PS)이 노출되고, PS에 친화성을 가진 ANNEXIN V-FITC는 PS과 결합하게 된다. 이러한 성질 때문에 ANNEXIN V-FITC 염색은 pheophorbide a-TEG 덴드론 컨쥬게이트에 의한 apoptosis(세포자살)를 관찰하는 지표로 사용될 수 있다. When apoptosis of cancer cells occurs, the phosphatidylserine (PS) is exposed and the ANNEXIN V-FITC, which is affinity to PS, binds to PS because the phospholipid asymmetry is lost. Because of this property, ANNEXIN V-FITC staining can be used as an indicator of apoptosis (apoptosis) by the pheophorbide a-TEG dendron conjugate.
Pheophorbide a-TEG 덴드론 컨쥬게이트의 경우 ce6와 비교해서 상대적으로 형광강도가 증대한 것으로 나타났고, 고효율 광민감성 치료소재로서의 이용가능성을 시사하였다.The fluorescence intensity of pheophorbide a-TEG dendron conjugate was relatively increased compared to ce6, suggesting its potential for use as a high-efficiency light-sensitive therapeutic material.
이상, 본 발명내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.
Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (6)
[화학식 1]
1. A photosensitizer for photodynamic diagnosis or treatment represented by the following formula (1).
[Chemical Formula 1]
상기 광감작제는 650 내지 700 nm의 광선에 대하여 광감작 활성을 나타내는 것을 특징으로 하는 광역학 진단 또는 치료용 광감작제.
The method according to claim 1,
Wherein the photosensitizer exhibits photosensitizing activity against light rays of 650 to 700 nm.
상기 광감작제는 고형암을 광역학적으로 진단 또는 치료하는 것을 특징으로 하는 광역학 진단 또는 치료용 광감작제.
The method according to claim 1,
Wherein said photosensitizer is a photodynamic diagnostic or therapeutic agent for photodynamic diagnosis, characterized in that said solid tumor is photodynamically diagnosed or treated.
(2) 감압 여과하는 단계;
(3) 용매를 이용하여 추출하고 용매를 제거하는 단계; 및
(4) 칼럼 크로마토그래피로 분리하는 단계;
를 포함하는 하기 화학식 1로 표시되는 광역학 진단 또는 치료용 광감작제의 제조방법.
[화학식 1]
(1) dissolving pheophorbide a and triethylene glycol dendron in a solvent, mixing, and stirring;
(2) vacuum filtration;
(3) extracting with a solvent and removing the solvent; And
(4) separating by column chromatography;
Wherein the photodynamic agent is represented by the following general formula (1).
[Chemical Formula 1]
상기 (1)단계에서 TEG 덴드론(triethylene glycol dendron)은 1,3-DCC(1,3-dicyclohexyl carbodiimide) 및 4-DMAP(4-dimethyaminopyridine)와 함께 용매에 녹여 pheophorbide a와 혼합하는 것을 특징으로 하는 광역학 진단 또는 치료용 광감작제의 제조방법.
5. The method of claim 4,
In step (1), the TEG dendron is dissolved in a solvent together with 1,3-DCC (1,3-dicyclohexyl carbodiimide) and 4-DMAP (4-dimethylaminopyridine) and mixed with pheophorbide a Wherein the photothermographic material is a photothermographic material.
상기 (1)단계에서 교반하는 시간은 40 내지 50 시간인 것을 특징으로 하는 광역학 진단 또는 치료용 광감작제의 제조방법.
5. The method of claim 4,
Wherein the agitation time in the step (1) is 40 to 50 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130020892A KR101493889B1 (en) | 2013-02-27 | 2013-02-27 | Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130020892A KR101493889B1 (en) | 2013-02-27 | 2013-02-27 | Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140106814A true KR20140106814A (en) | 2014-09-04 |
| KR101493889B1 KR101493889B1 (en) | 2015-03-09 |
Family
ID=51754935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130020892A KR101493889B1 (en) | 2013-02-27 | 2013-02-27 | Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101493889B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160053082A (en) * | 2014-10-30 | 2016-05-13 | 건국대학교 산학협력단 | Water soluble chlorine derivative with photoactivity and preparation method thereof |
| KR20160053083A (en) * | 2014-10-30 | 2016-05-13 | 건국대학교 산학협력단 | Water soluble photosensitizer with polysilsesquioxane core and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102294477B1 (en) * | 2019-10-17 | 2021-08-25 | 경희대학교 산학협력단 | Novel use of Epimedium koreanum Nakai extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050027197A (en) * | 2004-08-19 | 2005-03-18 | (주)피디티바이오 | Noble porphyrin compounds |
-
2013
- 2013-02-27 KR KR1020130020892A patent/KR101493889B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160053082A (en) * | 2014-10-30 | 2016-05-13 | 건국대학교 산학협력단 | Water soluble chlorine derivative with photoactivity and preparation method thereof |
| KR20160053083A (en) * | 2014-10-30 | 2016-05-13 | 건국대학교 산학협력단 | Water soluble photosensitizer with polysilsesquioxane core and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101493889B1 (en) | 2015-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5567024B2 (en) | Method for producing chlorin and its use as a medicament | |
| US8747811B2 (en) | Perylenequinone derivatives and uses thereof | |
| Li et al. | Synthesis and biological evaluation of peptide-conjugated phthalocyanine photosensitizers with highly hydrophilic modifications | |
| EP2931728B1 (en) | Chlorin derivative useful in photodynamic therapy and diagnosis | |
| CN108070275B (en) | Squaric acid dye compound, preparation method and application | |
| EP3215586B1 (en) | Selective cancer tracking eradicator and the uses thereof | |
| JP2019533635A (en) | Novel dihydroporphine e6 derivative and pharmaceutically acceptable salt thereof, preparation method and use thereof | |
| WO2000033833A1 (en) | Palladium-substituted bacteriochlorophyll derivatives and use thereof | |
| CN103864833B (en) | A kind of axial end hydroxyl replaces silicon phthalocyanine and self-assembly thereof | |
| KR101493889B1 (en) | Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method | |
| Liu et al. | A near-infrared and lysosome-targeted BODIPY photosensitizer for photodynamic and photothermal synergistic therapy | |
| Köse et al. | Synthesis of a novel axially substituted silicon phthalocyanine sensitizer for efficient singlet oxygen generation by comparing PDT and SPDT studies | |
| Ünlü et al. | Synthesis of axially Schiff base new substituted silicon phthalocyanines and investigation of photochemical and sono-photochemical properties | |
| CN105582541B (en) | The graphene oxide of Pegylation-Porphyrin dimer salt composite and application thereof | |
| JP2021528482A (en) | Oxazine compounds and their use | |
| Peng et al. | Nir laser-activated phthalocyanine loaded lipid nanoparticles targeting M2 macrophage for improved photoacoustic imaging-guided photothermal therapy | |
| KR101847486B1 (en) | Porphyrin derivative having hydrophilic group and hydrophobic group, and process for preparing the same | |
| RU2548675C2 (en) | Amino amides in bacteriochlorophyll alpha series, having photodynamic activity and method for production thereof | |
| Yan | EVALUATION OF PORPHYRIN DERIVATIVE FOR PHOTODYNAMIC THERAPY | |
| KR101643297B1 (en) | Water soluble chlorine derivative with photoactivity and preparation method thereof | |
| KR20160053084A (en) | Photosensitizer based on aqueous porphyrin-fullerene conjugates and preparation method thereof | |
| Le An | Development of porphyrinoid-based photosensitisers as potentially dual acting agents for photodynamic therapy and crosslinkable polymeric contrast agent for high-resolution x-ray imaging of the vascular system | |
| Kim et al. | Gadolinium-chlorin is potentially a new tumor specific MRI contrast agent | |
| KR20230057188A (en) | Composition of anticancer agent with photoactive combination therapy and producing method thereof | |
| WO2011031955A2 (en) | Optical monitoring of leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| FPAY | Annual fee payment |
Payment date: 20180202 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190207 Year of fee payment: 5 |